1 year return (CAGR)
-14.90%
Audax Renovables S.A. Exchange (MC, EUR)
ADX.MC
1.14
+0.03 (+3.07%)
UtilitiesUtilities - Renewable
Loading...
3 year return (CAGR)
-3.83%
5 year return (CAGR)
-1.38%
10 year return (CAGR)
8.61%
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
507.97M
Price/Sales
0.27
Ent value
1.39B
Price/Book
2.15
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
-1.24%
Trailing P/E
42.52
PEG
-
Forward P/E
10.38
EPS growth
-6.20%
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 1.12 |
| Daily high | 1.17 |
| Daily low | 1.11 |
| Daily Volume | 739K |
| All-time high | 9.72 |
| 1y analyst estimate | 2.35 |
| Beta | 1.11 |
| EPS (TTM) | 0.03 |
| Dividend per share | 0.00 |
| Ex-div date | 1 Jul 2026 |
| Next earnings date | 28 Feb 2026 |
Downside potential
Loading...
Downside potential data
| ADX.MC | S&P500 | |
| Current price drop from All-time high | -88.25% | -3.39% |
| Highest price drop | -97.22% | -56.47% |
| Date of highest drop | 25 Apr 2013 | 9 Mar 2009 |
| Avg drop from high | -80.37% | -10.64% |
| Avg time to new high | 71 days | 12 days |
| Max time to new high | 4934 days | 1805 days |
News
TG Therapeutics is Tuesday's IBD Stock Of The Day. Shares topped a buy zone despite a mixed Q3 report, but are in range of an alternate entry.
November 10, 2026
PepGen reports solid trial data for its rare-disease candidate, pressuring rivals developing competing therapies for myotonic dystrophy type 1.
November 10, 2026
PepGen Inc. (NASDAQ:PEPG) stock surged on Tuesday with a strong session Volume of 31.855 million, compared to an average volume of 983.011 thousand, according to Benzinga Pro data. The clinical-stage ...
November 10, 2026
INFORMATION REGARDING THE TOTAL VOTING RIGHTS AND SHARES OF KLÉPIERRE SA AS OF OCTOBER 31, 20261 Paris – November 10, 2026 NUMBER OF SHARES AS OF OCTOBER 31, 2026 Date10/31/2026Company nameKlépierreTr...
November 10, 2026
Patients continuing ianalumab saw further improvement in systemic disease activity through Week 108, with no new safety findings1 Nearly two-thirds of patients on continuous ianalumab reached low dise...
November 10, 2026
What risks do companies face as AI transforms the workplace—and what do they risk losing in pursuit of greater productivity? Former Novartis CEO Joe Jimenez discusses what businesses need to consider ...
November 10, 2026
IMVIONIX Inc., a privately held biotechnology company dedicated to advancing the delivery of retinal therapies, today announced that it has acquired exclusive commercial rights to BEOVU® (brolucizumab...
November 10, 2026
Target diagnostics, therapeutics and AI-enabled analytics to unlock revenue opportunities, improve treatment efficacy and reduce healthcare costsDublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Personalized...
November 10, 2026
Exmar has delivered a very strong multi‑year share-price run, and that kind of move naturally raises a blunt question for investors who care about what they are paying for. Is the current price around...
November 10, 2026
Novartis retains first place ranking among 20 sector peers for efforts to improve access to medicinesFirst company to achieve No. 1 rank across all Technical Areas since Index began in 2008, achieving...
November 10, 2026